Ultragenyx FDA-Approved Treatment Shows Sustained Reduction in Cornstarch Intake
Ultragenyx reports positive 96-week Phase 3 results for GENGLYCOS in GSDIa patients, showing sustained daily cornstarch reductions.
Ultragenyx's new medicine helped patients with a rare disease need less cornstarch for 96 weeks, which means the treatment keeps working over a long time. When a company shows their medicine works well and lasts, it can make people more confident the company might do well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.